Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate
insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 …

Abstract Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions
through an anchored transmembrane molecule and a soluble circulating protein. Both …

Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in
high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid …

Digested dietary fats are taken up by enterocytes where they are assembled into pre-
chylomicrons in the endoplasmic reticulum followed by transport to the Golgi for maturation …

The intestine represents the body's largest interface between internal organs and external
environments except for its nutrient and fluid absorption functions. It has the ability to sense …

The discovery of incretin-based medications represents a major therapeutic advance in the
pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid …

Dietary lipids are efficiently absorbed by the small intestine, incorporated into triglyceride-
rich lipoproteins (chylomicrons), and transported in the circulation to various tissues …

Postprandial hyperlipidaemia is an important feature of diabetic dyslipidaemia and plays an
important role in the development of cardiovascular disease in individuals with type 2 …

Lymphatic system is a key target in research field due to its distinctive makeup and huge
contributing functions within the body. Intestinal lymphatic drug transport (chylomicron …